🔍

GUFICBIO - Gufic BioScience

📊 NSE: GUFICBIO 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 22:40

📢 Recent Corporate Announcements

Gufic Biosciences Pays ₹1.72 Lakh Penalty to BSE After Waiver Rejection

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 13 Mar 2026, 07:49 PM

Gufic Biosciences has paid a penalty of ₹1,72,000 to BSE following the rejection of its waiver application regarding non-compliance with SEBI listing regulations. The penalty was imposed for appointing Mr. Kamal Kishore Seth as an Independent Director, who was over 75 years old, without obtaining shareholder approval via a special resolution. The company had previously paid a smaller penalty of ₹8,000 for the quarter ended June 2024. This payment settles the regulatory dispute for the quarters ended June and September 2024.

BSE rejected the company's waiver application for penalties related to Regulation 17(1A) non-compliance.
Penalty of ₹1,72,000 (excluding GST) paid to BSE for the quarter ended September 30, 2024.
Previously paid ₹8,000 (excluding GST) to both BSE and NSE for the quarter ended June 30, 2024.
Non-compliance involved the appointment of a director over 75 years old without a special resolution.
The financial impact is negligible relative to the company's overall scale.

💡 This is a minor administrative and procedural lapse with no material impact on the company's financials. Investors should treat this as a routine regulatory update and continue to monitor the company's core business performance.

Gufic Biosciences Releases Written Transcript of Feb 16 Earnings Conference Call

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 20 Feb 2026, 05:02 PM

Gufic Biosciences Limited has released the official written transcript of its earnings conference call held on February 16, 2026. This document provides a detailed record of the management's discussion regarding the company's recent financial performance and strategic outlook. The filing is a routine regulatory requirement under SEBI (LODR) Regulations, 2015. Investors can access the full text on the company's website to gain deeper insights into operational nuances not captured in the summary results.

Written transcript of the earnings call held on February 16, 2026, at 04:30 p.m. is now available.
The disclosure is made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The transcript provides management commentary on the company's quarterly performance and future growth drivers.
The document is publicly accessible via the company's official website link provided in the filing.

💡 Investors should read the transcript to understand management's guidance on the lyophilization business and R&D pipeline. It serves as a vital tool for fundamental analysis and assessing management's transparency.

Gufic Bio Q3 Net Profit Declines 35% YoY to ₹12.4 Cr; Revenue Up 11% YoY

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 10:29 PM

Gufic Biosciences reported a consolidated revenue of ₹231.4 crore for Q3 FY26, marking an 11.3% growth compared to the same quarter last year. However, net profit for the quarter fell sharply by 35.6% YoY to ₹12.4 crore, down from ₹19.3 crore in Q3 FY25. The profitability was primarily impacted by a significant rise in finance costs, which nearly doubled for the nine-month period to ₹27.2 crore. Additionally, the company announced a small strategic investment of up to USD 50,000 in Selvax Pty Ltd to acquire 3,78,350 ordinary shares.

Consolidated Revenue for Q3 FY26 stood at ₹231.4 crore, up 11.3% YoY but down 2.4% QoQ.
Consolidated Net Profit for the quarter was ₹12.4 crore, a 35.6% decline from ₹19.3 crore in Q3 FY25.
Finance costs for the nine-month period ended Dec 2025 surged to ₹27.2 crore from ₹14.7 crore YoY.
9M FY26 Basic EPS dropped to ₹4.22 compared to ₹6.18 in 9M FY25.
Board approved further investment in Selvax Pty Ltd at AUD 20 cents per share, totaling up to USD 50,000.

💡 Investors should exercise caution as the company is facing significant margin pressure from rising interest and depreciation costs despite steady revenue growth. It is important to monitor the company's debt-servicing capability and the performance of its international subsidiaries.

Gufic Biosciences Targets 30% Indore Plant Utilization and EBITDA Breakeven in FY26

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 13 Feb 2026, 10:25 PM

Gufic Biosciences has operationalized its advanced Indore facility as of October 2024, which features a monthly capacity of 5 million lyophilized vials and 6 million liquid vials. The company has already secured 203 product approvals for this facility and completed tech transfers for 40 products. Management expects the Indore unit to achieve EBITDA breakeven in FY26 at 30% utilization and become margin accretive by FY27. The strategic focus remains on high-growth platforms including Critical Care, Women's Health (IVF), and Botulinum Toxin (Aesthetics).

Indore facility monthly capacity includes 5 million lyophilized vials, 6 million liquid vials, and 10 million ampoules.
Targeting 30% capacity utilization and EBITDA breakeven for the Indore facility during FY26.
Received 203 product approvals from State FDA for the Indore unit with more in the pipeline.
EU GMP and UK MHRA regulatory clearances for the new facility are targeted for Q1-FY27.
Strong growth in specialized brands like Guficin Alpha in the Reproductive Immunology segment.

💡 Investors should track the quarterly utilization rates of the Indore facility and the progress of EU GMP/UK MHRA audits in early FY27 as these are key catalysts for export growth. The company's transition from a pure-play manufacturer to a specialized platform provider in aesthetics and IVF offers potential for long-term margin expansion.

Gufic Bio Q3 Results: Revenue up 11% YoY to ₹231 Cr, PAT drops 35% to ₹12.4 Cr

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 10:07 PM

Gufic Biosciences reported a mixed performance for Q3 FY26, with consolidated revenue growing 11.3% YoY to ₹231.41 crore. However, the bottom line was significantly impacted, with consolidated net profit falling 35.6% YoY to ₹12.42 crore, primarily due to a sharp rise in finance costs and depreciation. For the nine-month period ending December 2025, PAT stands at ₹42.32 crore, down from ₹61.93 crore in the previous year. Additionally, the company approved a small strategic investment of up to USD 50,000 in Australia-based Selvax Pty Ltd.

Consolidated Revenue from operations increased 11.3% YoY to ₹231.41 crore in Q3 FY26.
Consolidated Net Profit declined by 35.6% YoY to ₹12.42 crore from ₹19.31 crore.
Finance costs surged 70% YoY to ₹8.36 crore, while depreciation expenses rose 66% to ₹7.69 crore.
9-month FY26 consolidated PAT fell to ₹42.32 crore compared to ₹61.93 crore in 9M FY25.
Board approved further investment in Selvax Pty Ltd, Australia, for 3,78,350 shares at AUD 0.20 each.

💡 Investors should be cautious as rising interest and depreciation costs are significantly eroding profitability despite steady revenue growth. Monitor the company's debt levels and the commissioning of new projects that might be driving these higher expenses.

Gufic Bio Q3 Results: Revenue Up 11% YoY to ₹231 Cr, Net Profit Drops 35% to ₹12.4 Cr

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 09:59 PM

Gufic Biosciences reported a mixed performance for Q3 FY26, with consolidated revenue growing 11.4% year-on-year to ₹231.41 crore. However, net profit saw a sharp decline of 35.6% YoY, falling to ₹12.42 crore from ₹19.31 crore in the previous year's quarter. This bottom-line pressure was primarily driven by a significant rise in finance costs and depreciation expenses. Additionally, the company announced a small strategic investment of up to USD 50,000 in Australia-based Selvax Pty Ltd.

Consolidated revenue from operations increased 11.4% YoY to ₹231.41 crore.
Net profit declined 35.6% YoY to ₹12.42 crore, with EPS falling from ₹1.93 to ₹1.24.
Finance costs surged by 70% YoY to ₹8.36 crore, impacting overall margins.
Depreciation and amortization expenses rose to ₹7.69 crore from ₹4.62 crore in the year-ago period.
Board approved a further investment of USD 50,000 in Selvax Pty Ltd for 3,78,350 ordinary shares.

💡 Investors should remain cautious as the company is experiencing significant margin compression due to rising interest and depreciation costs despite steady revenue growth. It is important to monitor if the current capital expenditure leads to better operational efficiencies in the coming quarters.

Gufic Biosciences Schedules Q3 FY26 Earnings Conference Call for February 16, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Feb 2026, 07:06 PM

Gufic Biosciences Limited has scheduled its Q3 FY26 earnings conference call for Monday, February 16, 2026, at 4:30 PM IST. The company's management will discuss the financial performance and future business prospects during the session. This is a standard regulatory filing under SEBI (LODR) Regulations, 2015. Investors and analysts can join via domestic dial-in numbers or international toll-free lines provided for the US, UK, Singapore, and Hong Kong.

Earnings conference call set for February 16, 2026, at 16:30 IST
Management to discuss Q3 FY26 financial results and business outlook
Domestic dial-in numbers: +91 22 6280 1390 and +91 22 7115 8390
International access provided for major financial hubs including USA (1 866 746 2133) and UK (0 808 101 1573)

💡 Investors should track the call for management commentary on margin trends and the progress of new product launches. It is a good opportunity to assess the company's growth guidance for the remainder of the fiscal year.

Gufic Biosciences to Participate in Systematix India Annual Conference on Feb 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 06:23 PM

Gufic Biosciences Limited has scheduled an interaction with analysts and institutional investors on February 09, 2026. The meeting will take place at the 'Manthan – Systematix India Annual Flagship Conference' in Mumbai. The company will participate in both one-on-one and group sessions to discuss business developments based on publicly available information. This engagement is part of the company's routine investor relations activities to maintain transparency with the financial community.

Investor meeting scheduled for February 09, 2026, in Mumbai.
Participation in the Manthan – Systematix India Annual Flagship Conference.
Format includes both one-on-one and group in-person interactions.
Company confirms no unpublished price sensitive information (UPSI) will be shared during the meet.

💡 No immediate action is required as this is a routine disclosure. Investors should monitor for any investor presentations or transcripts released after the event for potential insights into the company's strategy.

Gufic Biosciences Receives Income Tax Demand Notice of Rs 4.33 Crore

🟡 NEUTRAL ⭐ 4/10

LEGAL 📅 20 Jan 2026, 07:44 PM

Gufic Biosciences Limited has received a tax demand notice of Rs 4.33 crore from the Income Tax Department for the Assessment Year 2024-25. The demand stems from the disallowance of certain expenditures during the assessment process under Section 143(1)(a) of the Income Tax Act. The company received the formal order on January 19, 2026, and has expressed its intention to contest the demand. Management is currently preparing to file an appeal before the Commissioner of Income Tax (Appeals), citing a strong legal position.

Tax demand aggregating to Rs 4,33,36,680 raised for Assessment Year 2024-25.
The demand is attributed to the disallowance of expenditure under Section 143(1)(a) of the Income Tax Act.
Order was dated December 22, 2025, and officially received by the company on January 19, 2026.
Company plans to file an appeal with the Commissioner of Income Tax (Appeals) within the prescribed time limit.
Management expects a favorable outcome based on advice from tax consultants and prevailing laws.

💡 Investors should treat this as a routine tax dispute; the amount is not significantly material to the company's overall operations. Monitor for future updates regarding the outcome of the appeal process.

Gufic Biosciences Submits Routine SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 07:11 PM

Gufic Biosciences has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ended December 31, 2025. The certificate, issued by Registrar MUFG Intime India Private Limited, confirms that all regulatory requirements regarding the dematerialization of shares were met. Interestingly, the report notes that no dematerialization requests were received from shareholders during this specific quarter. This is a standard administrative filing required by Indian stock exchanges to ensure the integrity of the company's share register.

Compliance certificate filed for the quarter ended December 31, 2025.
MUFG Intime India Private Limited (formerly Link Intime) confirmed as the RTA.
Zero dematerialization requests were received from shareholders during the quarter.
Confirmation that all previously issued securities remain properly listed on BSE and NSE.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial results for performance insights.

Gufic Biosciences to Close Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Dec 2025, 04:55 PM

Gufic Biosciences Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI insider trading regulations. This closure is ahead of the board's consideration of the unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are declared. The specific date for the board meeting to approve these results will be announced separately in due course.

Trading window closure effective from Thursday, January 01, 2026.
Closure pertains to the financial results for the quarter and nine months ended December 31, 2025.
Window to reopen 48 hours after the official declaration of standalone and consolidated results.
Restriction applies to all Designated Persons and their immediate relatives as per SEBI norms.

💡 This is a routine regulatory announcement with no direct impact on stock valuation. Investors should await the announcement of the board meeting date to assess the company's Q3 FY26 financial performance.

Gufic Biosciences Receives GST Penalty Order of ₹15.64 Lakhs

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 27 Dec 2025, 10:16 PM

Gufic Biosciences has received a tax order from the CGST authority imposing penalties totaling approximately ₹15.64 Lakhs. The demand pertains to alleged excess Input Tax Credit and short tax payments for the period between FY 2018-19 and FY 2022-23. The company has expressed its intention to appeal the order before the relevant authorities. Management maintains that this order will not have any material impact on the company's financial or operational performance.

Total penalty of ₹15,64,052 imposed by the Office of the Superintendent CGST, Ghaziabad.
Penalty of ₹15,35,080 relates to alleged excess Input Tax Credit (ITC) claimed between FY 2018-19 and FY 2022-23.
Additional penalty of ₹28,972 levied for alleged short payment of tax liability.
The company intends to file an appeal and expects a favorable outcome at the tribunal level.
Management confirms no material impact on financial operations or other activities.

💡 The penalty amount is immaterial relative to the company's scale of operations; investors should view this as a routine regulatory matter and monitor the outcome of the appeal.

View All GUFICBIO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Infertility division is a key growth driver; Critical Care and Sparsh divisions grew 8-10% in volume, though value growth was limited to 4-6% due to API price erosion. CMO business declined in H1 FY26 as capacity was prioritized for higher-margin exports.

Geographic Revenue Split

International business currently contributes 20-25% of total revenue, with management targeting an increase to 30-35% to drive gross margin expansion. Domestic business remains the primary contributor at approximately 75-80%.

Profitability Margins

Gross margins improved in Q2 FY26 due to a better sales mix and increased international business. PAT margin improved to 6.47% in Q2 FY26 from 5.32% in Q1 FY26. Operating margins are expected to remain stable above 15% over the medium term.

EBITDA Margin

EBITDA margin stood at 16.45% in Q2 FY26 (INR 37.9 Cr), up 182 bps from 14.63% in Q1 FY26 (INR 33.2 Cr). The improvement is attributed to higher-margin international sales and better absorption of fixed costs as the Indore plant scales.

Capital Expenditure

The company recently completed a major capex of INR 360 Cr for the Indore plant which commenced operations in early 2025. Future maintenance capex is projected at INR 15-20 Cr for the next 12 months.

Credit Rating & Borrowing

Long-term rating of [ICRA]A- (Stable) and Short-term rating of [ICRA]A2+. Interest coverage ratio was robust at 5.7 times in FY25. Average fund-based limit utilization is approximately 57-78%.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) represent the primary raw material cost. Specific API names are not listed, but they are subject to price volatility which is passed through in CMO contracts.

Import Sources

A significant portion of raw materials is imported to support the formulations business, though specific countries are not detailed in the provided documents.

Key Suppliers

Not specifically named in the documents; however, the company maintains healthy relationships with a broad base of suppliers to mitigate procurement risks.

Capacity Expansion

Indore plant is currently at 25% production capacity and 23% sales utilization as of Q2 FY26. Navsari plant is operating at 100% utilization. The Indore plant is designed to meet USFDA standards to support future export growth.

Raw Material Costs

Raw material costs are susceptible to global price fluctuations; however, a downward trend in API prices recently led to price reductions for end-customers in the Critical Care segment to maintain market share.

Manufacturing Efficiency

Focus is shifting from CMO to own-branded products and exports to maximize returns on the INR 360 Cr Indore investment. Indore is currently scaling up with 40 molecules already transferred.

Logistics & Distribution

Distribution is managed through a hybrid model; the company recently reverted to a primary billing model (selling to stockists) to reduce working capital intensity from the previous direct-to-hospital model.

📈 Strategic Growth

Expected Growth Rate

15-20%

Growth Strategy

Growth will be driven by the ramp-up of the Indore facility, increasing the share of international business to 30-35%, and launching new products like Semaglutide (GLP-1) in partnership with Hetero. The company is also expanding into regulated markets like Canada, South Africa, and Brazil.

Products & Services

Lyophilised injectables, infertility hormones, Critical Care medicines, Sparsh division products, and aesthetic products like Botox.

Brand Portfolio

Stunnox (Botox), Puregraf, Guficin Alpa, Supergraf (Infertility), and various hospital-first injectable platforms.

New Products/Services

Launch of Semaglutide (GLP-1) as a CMO for Hetero expected in Q1 FY27 following patent expiry in March 2026. Continued expansion of the Botox (Stunnox) portfolio.

Market Expansion

Targeting regulated and semi-regulated international markets including the US (pending FDA approval), Canada, South Africa, and Brazil.

Strategic Alliances

Strategic CMO partnership with Hetero for Remdesivir and Semaglutide (GLP-1).

🌍 External Factors

Industry Trends

The industry is shifting toward specialized delivery systems like lyophilization. Gufic is positioning itself as a leader in this niche with its new Indore plant, moving away from low-margin CMO work toward high-value branded exports.

Competitive Landscape

Intense competition from both large multinational pharmaceutical companies and established domestic players like Zydus and Lupin.

Competitive Moat

Moat is built on specialized manufacturing capabilities in lyophilised injectables and a strong hospital-first distribution network. Sustainability depends on maintaining high quality standards and securing international regulatory approvals.

Macro Economic Sensitivity

The pharmaceutical industry is relatively resilient to GDP fluctuations but sensitive to healthcare policy changes and government spending.

Consumer Behavior

Increasing demand for aesthetic treatments (Botox) and infertility treatments is driving growth in the company's specialized divisions.

Geopolitical Risks

Trade barriers or regulatory changes in target export markets (Brazil, South Africa) could impact the international expansion strategy.

⚖️ Regulatory & Governance

Industry Regulations

Operations are highly regulated by state and central agencies (CDSCO) regarding drug pricing (DPCO), manufacturing standards (GMP), and clinical trials.

Environmental Compliance

The company conducts regular training and awareness programs to ensure compliance with environmental and social requirements inherent in pharma manufacturing.

Taxation Policy Impact

The company noted a steep increase in current tax effects in Q2 FY26, partly related to cash management and timing of payments.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the timeline for receiving international regulatory approvals (e.g., USFDA) for the Indore plant, which is critical for achieving the 15-20% growth target.